Strategic Acquisition InferMed was acquired by Elsevier in 2015, indicating a successful exit and continued integration within a larger information and analytics ecosystem. This history suggests opportunities to align with Elsevier’s healthcare content and CDS strategies, leveraging their broader customer base.

Clinical Decision Support With Arezzo decision support technology and MACRO EDC, InferMed offers evidence-based, point-of-care guidance. This positions the company to target healthcare providers and research organizations seeking scalable CDS and data capture solutions to improve adherence to best practices.

Global Reach Solutions accessed over a million times per month across Europe, North America and Australasia indicate multinational adoption and regulatory experience. Potential sales opportunities exist in multinational clinics and hospitals seeking interoperable CDS and data workflows.

Modest Revenue, Large Upsell Potential Current revenue is in the zero to one million range, suggesting early-stage monetization with room to grow through expanded licenses, enterprise deployments, and expanded modules or services leveraging Arezzo and EDC capabilities.

Healthcare Outcomes Queen’s Award for Enterprise in Innovation highlights a track record of improving clinical care quality and standardization. This can be a compelling value proposition for customers prioritizing patient safety, regulatory compliance, and measurable outcomes.